Is the cure worth the treatment?

In this episode of OutSmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explores one of the toughest questions in oncology — why so many cancer treatments are harder on the body than the disease itself. He explains how maximum-dose chemotherapy can damage the immune system, cause painful side effects, and even drive resistance — while precision microdosing targets cancer more effectively with far less toxicity.

Using genetic mapping (DNA and RNA sequencing), spatial biology, and immune profiling, Dr. Prato shows how to match the right drug, dose, and delivery method to each patient’s unique cancer. From CIPI (Chemo-Immuno-Precision Injection) that delivers therapy directly into the tumor to immune-based cell treatments (AAIT) that train your own NK and dendritic cells to fight back — this is the next evolution of cancer care.

🎯 What You’ll Learn in This Episode:

• Why high-dose chemotherapy often does more harm than good
• How microdosed chemo (10%) kills tumors while sparing the immune system
• How interventional oncology delivers 100% of medicine directly to the tumor
• Why immune retraining with NK and dendritic cells improves long-term outcomes
• How detoxification and nutrition support immune recovery
• Why precision targeting led to 35x better responses and 43x better quality of life in published results*

*(See Outcomes Disclaimer Below)

“You don’t have to choose between treatment and quality of life — with precision, you can have both.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

Will cancer ever be cured — or are we just managing symptoms?

In this visionary episode, Dr. Dino Prato, founder of Envita Medical Centers, explores whether cancer can disappear — not just through early detection or conventional care, but by addressing root causes and using thousands of biological data points to map precise, targeted treatment plans.

🎯 What You’ll Learn:

• Why standard cancer care often uses just 24 data points to guide treatment
• How precision oncology uses DNA, RNA, immune profiling & spatial biology
• The connection between mitochondrial dysfunction, infections, toxins, and cancer
• How liquid biopsy and non-invasive detection may stop cancer early — or before it starts
• Why many standard treatments create resistance, and what alternatives offer fewer side effects
• How to track remission using circulating tumor DNA (ctDNA) and methylation scores — not just scans

📊 According to Envita’s 2024 published data, patients treated with precision targeting showed 35x better outcomes, 43x improved quality of life, and 95x fewer side effects compared to historical norms.*
*(See Outcomes Disclaimer Below)

“Cancer may be complex — but it’s not unbeatable when your plan is precise.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

If your cancer treatment has failed — it doesn’t mean you’ve run out of hope.

In this deeply personal message, Dr. Dino Prato, founder of Envita Medical Centers, shares what happens when patients hit the end of the conventional oncology road. Many are told to go home, that no more can be done. But at Envita, we’ve helped thousands find personalized, precision-guided paths forward.

📊 In a 2024 study, our care model showed:

• 35x better clinical outcomes in late-stage cancer*

• 43x better quality of life*

• 95x fewer side effects, using advanced targeting and integrative support*
(*see outcomes disclaimer below)

🎯 What You’ll Learn:

• Why most patients we see were given the wrong chemo or integrative agents
• How precision testing (genomics, transcriptomics, immune profiling, spatial biology) opens new options
• Why mapping over 1,000 unique biomarkers can reveal treatments others miss
• Real-world case: A patient sent home from a major hospital entered remission with targeted care
• What you can do right now to stop the guesswork and start a new plan
• If you’re standing at a crossroads — unsure, exhausted, or afraid — you don’t have to do this alone. We’re here to guide you through next steps.

“You’re not out of options. You just haven’t been mapped correctly yet.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493